GLP-1 pricing heat rises as obesity drugs expand market at JPMorgan
At the JPMorgan Healthcare Conference, Novo Nordisk signals 2026 will bring price pressure as GLP-1 supply grows and pricing deals take effect, even as it pushes the Wegovy oral pill and expands the incretin market. Bristol Myers Squibb projects up to 10 new products by 2030 to counter upcoming exclusivity losses, while Pfizer insists it is “all in on obesity” and plans multiple late‑stage obesity studies tied to Metsera. The conference also features news such as Lilly and Nvidia jointly funding an AI drug‑discovery lab and AbbVie striking a price‑reduction deal with the Trump administration plus a RemeGen cancer-therapy license.
